SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Montana Wildhack who wrote (1601)4/8/1999 7:10:00 PM
From: Mark Bartlett  Read Replies (1) of 14101
 
Wolf,

First - thanks for your kind words.

I agree with you. I spoke with I/R yesterday and felt that there were meta-messages. He framed what he said in the following way "there are essentially 3 elements to the FDA's review, 1) safety, 2) efficacy, and 3) production facilities. Now - I understand the FDA wants to visit the production facilities in Montreal - this has to be arranged through the Canadian HPB - going to take a little time. But, I have to ask myself - if the efficacy and safety were issues, would the FDA bother visiting the production facilities? I suspect they would not bother - if the data is not there, what is the point.

Second - they are in the process of hiring additional scientific staff and product development staff .... again - why bother if Pennsaid was not looking pretty positive ... makes no sense.

Like you, these are just my opinions ... and like you I am long and heavy .... and if the price drops more - I am going to be longer and heavier.

Best to all,

MB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News